Last reviewed · How we verify
Fludarabine monophosphate, melphalan, Bortezomib
Fludarabine monophosphate, melphalan, Bortezomib is a Nucleoside analog, Alkylating agent, Proteasome inhibitor Small molecule drug developed by Hackensack Meridian Health. It is currently in Phase 2 development for Relapsed or refractory multiple myeloma, Mantle cell lymphoma. Also known as: Fludara, Phenylalanine Mustard, Velcade.
Fludarabine monophosphate is a purine analog that interferes with DNA synthesis, melphalan is an alkylating agent that cross-links DNA, and Bortezomib is a proteasome inhibitor that blocks protein degradation.
Fludarabine monophosphate is a purine analog that interferes with DNA synthesis, melphalan is an alkylating agent that cross-links DNA, and Bortezomib is a proteasome inhibitor that blocks protein degradation. Used for Relapsed or refractory multiple myeloma, Mantle cell lymphoma.
At a glance
| Generic name | Fludarabine monophosphate, melphalan, Bortezomib |
|---|---|
| Also known as | Fludara, Phenylalanine Mustard, Velcade |
| Sponsor | Hackensack Meridian Health |
| Drug class | Nucleoside analog, Alkylating agent, Proteasome inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fludarabine monophosphate works by incorporating into DNA and interfering with DNA synthesis, leading to cell death. Melphalan works by cross-linking DNA, causing DNA damage and cell death. Bortezomib works by blocking the proteasome, a complex that degrades proteins, leading to an accumulation of defective proteins and cell death.
Approved indications
- Relapsed or refractory multiple myeloma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (PHASE1)
- Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) (PHASE2)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma (PHASE2)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma (PHASE2)
- Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma (PHASE2)
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludarabine monophosphate, melphalan, Bortezomib CI brief — competitive landscape report
- Fludarabine monophosphate, melphalan, Bortezomib updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI
Frequently asked questions about Fludarabine monophosphate, melphalan, Bortezomib
What is Fludarabine monophosphate, melphalan, Bortezomib?
How does Fludarabine monophosphate, melphalan, Bortezomib work?
What is Fludarabine monophosphate, melphalan, Bortezomib used for?
Who makes Fludarabine monophosphate, melphalan, Bortezomib?
Is Fludarabine monophosphate, melphalan, Bortezomib also known as anything else?
What drug class is Fludarabine monophosphate, melphalan, Bortezomib in?
What development phase is Fludarabine monophosphate, melphalan, Bortezomib in?
What are the side effects of Fludarabine monophosphate, melphalan, Bortezomib?
Related
- Drug class: All Nucleoside analog, Alkylating agent, Proteasome inhibitor drugs
- Manufacturer: Hackensack Meridian Health — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory multiple myeloma
- Indication: Drugs for Mantle cell lymphoma
- Also known as: Fludara, Phenylalanine Mustard, Velcade
- Compare: Fludarabine monophosphate, melphalan, Bortezomib vs similar drugs
- Pricing: Fludarabine monophosphate, melphalan, Bortezomib cost, discount & access